The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.
 
Makenzi Colleen Evangelist
Consulting or Advisory Role - AADi; AstraZeneca; Daiichi Sankyo/Lilly; Mirati Therapeutics; Regeneron; Regeneron; Takeda; Takeda
 
James Edward Butrynski
Employment - US Oncology
Consulting or Advisory Role - Boehringer Ingelheim
 
John C. Paschold
Consulting or Advisory Role - AstraZeneca
 
Patrick J. Ward
Employment - Bon Secours Mercy Health (I)
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Fresenius Kabi BioSimilars
 
David Michael Waterhouse
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AZTherapies; Bristol-Myers Squibb; Daiichi; Eisai; EMD Serono; Exelixis; Fresenius Kabi; Gilead Sciences; Janssen Oncology; Jazz Pharmaceuticals; Lilly; McGivney Global Advisors; Merck; Mirati Therapeutics; Novats; Pfizer; Sanofi; Sanofi/Regeneron; Seagen; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Janssen Oncology; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Kashif Ali
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb
 
David Hakimian
Consulting or Advisory Role - CVS P+T
Travel, Accommodations, Expenses - US Oncology
 
Robert M. Jotte
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Roche; Mirati Therapeutics
 
Timothy Larson
No Relationships to Disclose
 
Michael W. Meshad
No Relationships to Disclose
 
Rami Owera
No Relationships to Disclose
 
Donald A. Richards
Consulting or Advisory Role - Grail; Ipsen; Mirati Therapeutics; Roche/Genentech; Seattle Genetics/Astellas; Taiho Pharmaceutical
 
Marcus A. Neubauer
Leadership - McKesson
Travel, Accommodations, Expenses - McKesson
 
Nicholas J Robert
Employment - McKesson
Leadership - McKesson
Stock and Other Ownership Interests - McKesson; Moderna Therapeutics; Oncolytics (I)
 
Jennifer L. Yori
Employment - Calithera Biosciences
Stock and Other Ownership Interests - Calithera Biosciences
 
Manoj Pant
No Relationships to Disclose
 
Robert L. Coleman
Employment - US Oncology; Vaniam Group
Leadership - Onxeo
Stock and Other Ownership Interests - McKesson/US Oncology Network
Consulting or Advisory Role - Abbvie; Agenus; Alkermes; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; GOG Foundation; Gradalis; Immunogen; Karyopharm Therapeutics; Merck; Merck; Novocure; OncoMed; OncXerna Therapeutics
Research Funding - Alkermes; Amgen (Inst); AstraZeneca/MedImmune; Clovis Oncology (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck; Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (I)
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Lyell Immunopharma (Inst); MedImmune (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Sanofi/Aventis (Inst)
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Asher Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Evelo Biosciences (Inst); Faeth Therapeutics (Inst); Foundation Bio (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Immunogen (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagen (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Strata Oncology (Inst); Synthekine (Inst); Taiho Oncology (Inst); Takeda (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis